54 research outputs found
Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study.
Cochrane corner: Is integrated disease management for patients with COPD effective?
Patients with COPD experience respiratory
symptoms, impairments of daily living and recurrent
exacerbations. The aim of integrated disease
management (IDM) is to establish a programme of
different components of care (ie, self-management,
exercise, nutrition) in which several healthcare providers
(ie, nurses, general practitioners, physiotherapists,
pulmonologists) collaborate to provide efficient and good
quality of care. The aim of this Cochrane systematic
review was to evaluate the effectiveness of IDM on
quality of life, exercise tolerance and exacerbation related
outcomes. Searches for all available evidence were
carried out in various databases. Included randomised
controlled trials (RCTs) consisted of interventions with
multidisciplinary (≥2 healthcare providers) and
multitreatment (≥2 components) IDM interventions with
duration of at least 3 months. Two reviewers
independently searched, assessed and extracted data of
all RCTs. A total of 26 RCTs were included, involving
2997 patients from 11 different countries with a followup
varying from 3 to 24 months. In all 68% of the
patients were men, with a mean age of 68 years and a
mean forced expiratory volume in 1 s (FEV1) predicted
value of 44.3%. Patients treated with an IDM
programme improved significantly on quality of life
scores and reported a clinically relevant improvement of
44 m on 6 min walking distance, compared to controls.
Furthermore, the number of patients with ≥1 respiratory
related hospital admission reduced from 27 to 20 per
100 patients. Duration of hospitalisation decreased
significantly by nearly 4 days
Exploring the variation in implementation of a COPD disease management programma and its impact on health outcomes
This study aims to (1) examine the variation in implementation of a 2-year chronic obstructive pulmonary disease (COPD) management programme called RECODE, (2) analyse the facilitators and barriers to implementation and (3) investigate the influence of this variation on health outcomes. Implementation variation among the 20 primary-care teams was measured directly using a self-developed scale and indirectly through the level of care integration as measured with the Patient Assessment of Chronic Illness Care (PACIC) and the Assessment of Chronic Illness Care (ACIC). Interviews were held to obtain detailed information regarding the facilitators and barriers to implementation. Multilevel models were used to investigate the association between variation in implementation and change in outcomes. The teams implemented, on average, eight of the 19 interventions, and the specific package of interventions varied widely. Important barriers and facilitators of implementation were (in)sufficient motivation of healthcare provider and patient, the h
Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease:Methodological Considerations and Recommendations
Worldwide, chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic lung disease with considerable clinical and socioeconomic impact. Pharmacologic maintenance drugs (such as bronchodilators and inhaled corticosteroids) play an important role in the treatment of COPD. The cost effectiveness of these treatments has been frequently assessed, but studies to date have largely neglected the impact of treatment sequence and the exact stage of disease in which the drugs are used in real life. We aimed to systematically review recently published articles that reported the cost effectiveness of COPD maintenance treatments, with a focus on key findings, quality and methodological issues. We performed a systematic literature search in Embase, PubMed, the UK NHS Economic Evaluation Database (NHS-EED) and EURONHEED (European Network of Health Economics Evaluation Databases) and included all relevant articles published between 2011 and 2015 in either Dutch, English or German. Main study characteristics, methods and outcomes were extracted and critically assessed. The Quality of Health Economic Studies (QHES) instrument was used as basis for quality assessment, but additional items were also addressed. The search identified 18 recent pharmacoeconomic analyses of COPD maintenance treatments. Papers reported the cost effectiveness of long-acting muscarinic antagonist (LAMA) monotherapy (n = 6), phosphodiesterase (PDE)-4 inhibitors (n = 4), long-acting beta agonist/inhaled corticosteroid (LABA/ICS) combinations (n = 4), LABA monotherapy (n = 2) and LABA/LAMA combinations (n = 2). All but two studies were funded by the manufacturer, and all studies indicated favourable cost effectiveness; however, the number of quality-adjusted life-years (QALYs) gained was small. Less than half of the studies reported a COPD-specific outcome in addition to a generic outcome (mostly QALYs). Exacerbation and mortality rates were found to be the main drivers of cost effectiveness. According to the QHES, the quality of the studies was generally sufficient, but additional assessment revealed that most studies poorly represented the cost effectiveness of real-life medication use. The majority of studies showed that pharmacologic COPD maintenance treatment is cost effective, but most studies poorly reflected real-life drug use. Consistent and COPD-specific methodology is recommended
Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial.
__Objective__ To investigate the long term effectiveness of integrated disease management delivered in primary care on quality of life in patients with chronic obstructive pulmonary disease (COPD) compared with usual care.
__Design__ 24 month, multicentre, pragmatic cluster randomised controlled trial
__Setting__ 40 general practices in the western part of the Netherlands
__Participants__ Patients with COPD according to GOLD (Global Initiative for COPD) criteria. Exclusion criteria were terminal illness, cognitive impairment, alcohol or drug misuse, and inability to fill in Dutch questionnaires. Practices were included if they were willing to create a multidisciplinary COPD team.
__Intervention__ General practitioners, practice nurses, and specialised physiotherapists in the intervention group received a two day training course on incorporating integrated disease management in practice, including early recognition of exacerbations and self management, smoking cessation, physiotherapeutic reactivation, optimal diagnosis, and drug adherence. Additionally, the course served as a network platform and collaborating healthcare providers designed an individual practice plan to integrate integrated disease management into daily practice. The control group continued usual care (based on
The Fold-in, Fold-out Design for DCE Choice Tasks: Application to Burden of Disease
Background. In discrete-choice experiments (DCEs), choice alternatives are described by attributes. The importance
of each attribute can be quantified by analyzing respondents’ choices. Estimates are valid only if alternatives are
defined comprehensively, but choice tasks can become too difficult for respondents if too many attributes are
included. Several solutions for this dilemma have been proposed, but these have practical or theoretical drawbacks
and cannot be applied in all settings. The objective of the current article is to demonstrate an alternative solution, the
fold-in, fold-out approach (FiFo). We use a motivating example, the ABC Index for burden of disease in chronic
obstructive pulmonary disease (COPD). Methods. Under FiFo, all attributes are part of all choice sets, but they are
grouped into domains. These are either folded in (all attributes have the same level) or folded out (levels may differ).
FiFo was applied to the valuation of the ABC Index, which included 15 attributes. The data were analyzed in
Bayesian mixed logit regression, with additional parameters to account for increased complexity in folded-out questionnaires and potential differences in weight due to the folding status of dom
ABC Index: quantifying experienced burden of COPD in a discrete choice experiment and predicting costs
OBJECTIVE: The Assessment of Burden of COPD (ABC) tool supports shared decision making between patient and caregiver. It includes a coloured balloon diagram to visualise patients' scores on burden indicators. We aim to determine the importance of each indicator from a patient perspective, in order to calculate a weighted index score and investigate whether that score is predictive of costs.DESIGN: Discrete choice experiment.SETTING AND PARTICIPANTS: Primary care and secondary care in the Netherlands. 282 patients with chronic obstructive pulmonary disease (COPD) and 252 members of the general public participated.METHODS: Respondents received 14 choice questions and indicated which of two health states was more severe. Health states were described in terms of specific symptoms, limitations in physical, daily and social activities, mental problems, fatigue and exacerbations, most of which had three levels of severity. Weights for each item-level combination were derived from a Bayesian mixed logit model. Weights were rescaled to construct an index score from 0 (best) to 100 (worst). Regression models were used to find a classification of this index score in mild, moderate and severe that was discriminative in terms of healthcare costs.RESULTS: Fatigue, limitations in moderate physical activities, number of exacerbations, dyspnoea at rest and fear of breathing getting worse contributed most to the burden of disease. Patients assigned less weight to dyspnoea during exercise, listlessness and limitations with regard to strenuous activities. Respondents from the general public mostly agreed. Mild, moderate and severe burden of disease were defined as scores <20, 20-39 and ≥40. This categorisation was most predictive of healthcare utilisation and annual costs: €1368, €2510 and €9885, respectively.CONCLUSIONS: The ABC Index is a new index score for the burden of COPD, which is based on patients' preferences. The classification of the index score into mild, moderate and severe is predictive of future healthcare costs.TRIAL REGISTRATION NUMBER: NTR3788; Post-results
The health economic impact of disease management programs for COPD: A systematic literature review and meta-analysis
__Abstract__
Background: There is insufficient evidence of the cost-effectiveness of Chronic Obstructive Pulmonary Disease (COPD) Disease Management (COPD-DM) programs. The aim of this review is to evaluate the economic impact of COPD-DM programs and investigate the relation between the impact on healthcare costs and health outcomes. We also investigated the impact of patient-, intervention, and study-characteristics.Methods: We conducted a systematic literature review to identify cost-effectiveness studies of COPD-DM. Where feasible, results were pooled using random-effects meta-analysis and explorative subgroup analyses were performed.Results: Sixteen papers describing 11 studies were included (7 randomized control trials (RCT), 2 pre-post, 2 case-control). Meta-analysis showed that COPD-DM led to hospitalization savings of €1060 (95% CI: €2040 to €80) per patient per year and savings in total healthcare uti
- …